Entrada Therapeutics

Q2 FY2026 EarningsQ2 FY2026 results were mixed relative to consensus: revenue of $0.90M missed the $2.23M estimate significantly (-59.8%), while Diluted EPS of -$1.01 was better than the expected -$1.10. The revenue shortfall was driven by a decline in collaboration revenue from the Vertex partnership. However, lower-than-expected R&D and G&A expenses led to a narrower net loss of $42.8M versus the $46.1M consensus, providing a cash runway into Q3 2027.